The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
MontogomeryJ, Shortnacy-FowlerA, ClaytonS, et al. Synthesis and biologic activity of 2’-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine. J Med Chem.1992;35(2):397–401.
2.
FaderlS, WetzlerM, RizzieriD, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: Results from the CLASSIC I Trial. J Clin Oncol.2012;30(20): 2492–2499.
3.
AguraE, CooperB, HolmesH, et al. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. Oncologist. 2011;16(2):197–206.
4.
FaderlS, VerstovsekS, CortesJ, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood.2006;108(1):45–51.
5.
FaderlS, RavandiF, HuangX, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood.2008;112(5):1638–1645.
6.
FaderlS, RavandiF, HuangX, et al. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer.2012;118(18):4471–4477.
7.
FaderlS, GandhiV, O'BrienS, et al. Results of a phase 1–2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood.2005; 105(3):940–947.
8.
Martínez-CuadrónD, MontesinosP, OriolA, et al. Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia. Ann Hematol.2014;93(1):43–46.
9.
BeckerP, KantarjianH, AppelbaumF, et al. Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia. Br J Haematol.2011;155(2):182–189.
10.
ScappiniB, GianfaldoniG, CaraccioloF, et al. Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients. Am J Hematol.2012;87(12):1047–1051.
11.
CooperTM, AlonzoTA, GerbingRB, et al. AAML0523: A report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. Cancer. 2014;120(16):2482–2489.
12.
InabaH, RubnitzJE, Coustan-Smith E, et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol.2011;29(24):3293–3300.
13.
MartinMG, UyGL, ProcknowE, et al. Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG. Bone Marrow Transpl.2009;44(1):13–17.
GelingO, EichlerHG. Should 5-Hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol.2005;23(6):1289–1294.
20.
TerreyJP, AaproMS. The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res.1996;8:281–288.
21.
CarmichaelJ, KeizerHJ, CupissolD, MilliezJ, ScheidelP, SchindlerAE. Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs.1998;9(5):381–385.
22.
de WitR, de BoerAC, vd LindenGH, StoterG, SparreboomA, VerweijJ.Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer.2001;19;85(8):1099–1101.
23.
SmithIE. A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. J Cancer Res Clin Oncol.1993;119(6):350–354.
24.
SoukopM.A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron Study Group. Support Care Cancer. 1994;2(3):177–183.
25.
SmithTJ, BohlkeKari, LymanGH, et al. Recommendations for the use of white blood cell growth factors: American Society of Clinical Oncology clinical practice guideline update. http://jco.ascopubs.org/content/early/2015/07/08/JCO.2015.62.3488. Accessed August 31, 2015.
BonatePL, CunninghamCC, GaynonP, et al. Population pharmacokinetics of clofarabine and its metabolite 6- ketoclofarabine in adult and pediatric patients with cancer. Cancer Chemother Pharmacol.2011;67(4):875–890.
29.
KintzelPE, DorrRT. Anticancer drug renal toxicity and elimination: Dosing guidelines for altered renal function. Cancer Treat Rev.1995;21(1):33–64.
AronoffGR, BennettWM, BernsJS, et al. Drug Prescribing in Renal Failure. 5th ed. Philadelphia: American College of Physicians; 2007.
32.
KorenG, BeattyK, SetoA, et al. The effects of impaired liver function on the elimination of antineoplastic agents. Ann Pharmacother.1992;26(3):363–371.
33.
FloydJ, MirzaI, Sachs, PerryMC. Hepatotoxicity of chemotherapy. Semin Oncol.2006;33:50–67.
34.
KingPD. PerryMC. Hepatotoxicity of chemotherapy. Oncologist. 2001;6(2):162–176.
